Top Abstract Purchase Preview Related
Home
>
Node
>
Subnode

An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression

Joffe, R.T.; Schuller, D.R.

Journal of Clinical Psychiatry 54(7): 269-271

1993

ISSN/ISBN: 0160-6689
PMID: 8335654
Document Number: 407838
Background: We evaluated the efficacy of buspirone in the augmentation of antidepressant response to the serotonin reuptake inhibitors. Method: Twenty-five patients with major depressive disorder who had failed several previous treatments for their current depressive episode were included. After failing a trial of fluoxetine or fluvoxamine, they received buspirone in addition to the serotonin reuptake inhibitor for 3 weeks in an open clinical trial. Results: Seventeen of 25 patients had a marked or complete antidepressant response. Conclusion: These data provide clinical evidence suggesting that buspirone augmentation may be a useful clinical alternative in depressed patients who fail to respond to a serotonin reuptake inhibitor.

Document emailed within 1 workday
Secure & encrypted payments

An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression

Phillips, K.A. 1996: An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder Psychopharmacology Bulletin 32(1): 175-180
Appelberg, B.G.; Syvälahti, E.K.; Koskinen, T.E.; Mehtonen, O.P.; Muhonen, T.T.; Naukkarinen, H.H. 2001: Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study Journal of Clinical Psychiatry 62(6): 448-452
Ostroff, R.B.; Nelson, J.C. 1999: Risperidone augmentation of selective serotonin reuptake inhibitors in major depression Journal of Clinical Psychiatry 60(4): 256-259
Posternak, M.A.; Zimmerman, M. 2005: Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study Journal of Clinical Psychiatry 66(6): 705-707
Marangell, L.B.; Johnson, C.R.; Kertz, B.; Zboyan, H.A.; Martinez, J.M. 2002: Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study Journal of Clinical Psychiatry 63(5): 391-395
Condat, A.; Mouren-Simeoni, M.C. 2000: Selective serotonin reuptake inhibitors and depression in the child and adolescent L'Encephale 26(3): 53-60
Wan, G.J.; Crown, W.H.; Berndt, E.R.; Finkelstein, S.N.; Ling, D. 2002: Healthcare expenditure in patients treated with venlafaxine or selective serotonin reuptake inhibitors for depression and anxiety International Journal of Clinical Practice 56(6): 434-439
Kulin, N.A.; Pastuszak, A.; Sage, S.R.; Schick-Boschetto, B.; Spivey, G.; Feldkamp, M.; Ormond, K.; Matsui, D.; Stein-Schechman, A.K.; Cook, L.; Brochu, J.; Rieder, M.; Koren, G. 1998: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study JAMA 279(8): 609-610
Fichtner, C.G.; Jobe, T.H.; Braun, B.G. 1994: Possible therapeutic window for serotonin reuptake inhibitors Journal of Clinical Psychiatry 55(1): 36-38
DeVane, C.L. 1992: Pharmacokinetics of the selective serotonin reuptake inhibitors Journal of Clinical Psychiatry 53 Suppl: 13-20
Leonard, B.E. 1988: Pharmacological effects of serotonin reuptake inhibitors Journal of Clinical Psychiatry 49 Suppl: 12-17
Dudek, D.; Zieba, A.; Siwek, M.; Wróbel, A. 2004: Selective serotonin reuptake inhibitors--current knowledge Psychiatria Polska 38(3): 507-524
Mayer, L.E.; Walsh, B.T. 1998: The use of selective serotonin reuptake inhibitors in eating disorders Journal of Clinical Psychiatry 59(Suppl): 28-34
Mahendran, R. 2006: The risk of suicidality with selective serotonin reuptake inhibitors Annals of the Academy of Medicine Singapore 35(2): 96-99
Eriksson, E. 1999: Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria International Clinical Psychopharmacology 14(Suppl 2): S27-S33
Sherman, T.L.; McDougle, C.J.; Price, L.H. 1993: Paroxetine: a new serotonin reuptake inhibitor for the treatment of depression Connecticut Medicine 57(9): 587-592
Nakielny, J.; Eckett, S. 1994: Selective serotonin reuptake inhibitors. Calculation of costs is incorrect Bmj 309(6961): 1082-3; Author Reply 1085
Dubovsky, S.L. 1994: Beyond the serotonin reuptake inhibitors: rationales for the development of new serotonergic agents Journal of Clinical Psychiatry 55(Suppl): 34-44
Sheehan, D.V.; Zak, J.P.; Miller, J.A.; Fanous, B.S. 1988: Panic disorder: the potential role of serotonin reuptake inhibitors Journal of Clinical Psychiatry 49 Suppl: 30-36
Tracey, D. 1994: Selective serotonin reuptake inhibitors. Commercial interests should not influence prescribing Bmj 309(6961): 1083-4; Author Reply 1085